In summary, our research conclusively demonstrates that CCR7 and ERK1/2 serve as crucial prognostic markers in DLBCL, with their interaction via the CCL21 pathway playing a pivotal role in tumor progression by activating ERK1/2. Here, CCL21 is linked to diffuse large B-cell lymphoma.